Open Access<p>Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder</p>
Author(s) -
Xiaoming Wang,
Yunjin Bai,
Facai Zhang,
Yubo Yang,
Dechao Feng,
Ao Li,
Zhiqiang Yang,
Dengxiong Li,
Yin Tang,
Xin Wei,
Wuran Wei,
Facai Zhang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s267734
Subject(s) - apoptosis , cancer research , gemcitabine , bladder cancer , viability assay , immunohistochemistry , medicine , biology , chemistry , cancer , biochemistry
Bladder cancer (BC) is a common malignancy worldwide that accounts for 3% of global cancer diagnoses. Chemotherapy resistance limits the therapeutic effect of chemotherapeutic agents in patients with BC. Prolyl 4-hydroxylase, beta polypeptide (P4HB) is an endoplasmic reticulum (ER) chaperone that is upregulated in bladder cancer tissues (The Cancer Genome Atlas, TCGA datasets). Knockdown or suppression of P4HB exerts anticancer activity and sensitizes cells to chemotherapy in various types of cancer.